CDC panel drops preference for MedImmune's FluMist
This article was originally published in Scrip
Executive Summary
A panel of advisers to the Centers for Disease Control and Prevention (CDC) last week dropped its preference for use in children 2-8 years of MedImmune's FluMist, the only FDA-approved intranasal live-attenuated influenza vaccine, citing new data showing there was no superior effectiveness of the product over the flu shot.